

## **SANOFI PASTEUR SUPPORTS WHO INITIATIVE FOR THE ESTABLISHMENT OF AN H5N1 VACCINE STOCKPILE**

**- Sanofi pasteur continues to commit resources and join the international community in enhancing pandemic preparedness to protect world health -**

**Lyon, France, June 13 2007** – Sanofi pasteur, the vaccines division of the sanofi-aventis Group, announced today that it is ready to supply a significant number of doses of H5N1 vaccine for the establishment of an international stockpile through a World Health Organization (WHO) partnership. Part of this supply could be made available immediately, in bulk form.

*“We have been part of the influenza vaccine history for half of a century and are pleased today to continue to partner with WHO to combat one of the world’s critical public health threats”* said Jean-François Dehecq, Chairman of sanofi-aventis. *“Above and beyond this vital initiative with the international community and with WHO, we are actively pursuing further moves that are intended to increase influenza vaccine supply for countries in the developing world, enabling us to provide a meaningful contribution to global pandemic preparedness”*.

Sanofi pasteur’s leadership position in developing and producing influenza vaccines places the company at the forefront of readiness against the threat of pandemic influenza. The company is committed to playing a leading role in case of a pandemic and sees its contribution in producing as many doses of sanofi pasteur’s most advanced vaccine in the shortest possible timeframe, should a pandemic be declared by the world’s health authorities.

### **Pandemic Influenza Overview**

Influenza is a disease caused by a highly infectious virus that spreads easily from person to person, primarily when an infected individual coughs or sneezes. An influenza pandemic is a global epidemic of an especially virulent virus, newly infectious for humans, and for which there is no preexisting immunity. This is why pandemic strains have such potential to cause severe morbidity and mortality. According to the World Health Organization (WHO), the next pandemic is likely to result in 1 to 2.3 million hospitalizations and 280,000 to 650,000 deaths in industrialized nations alone. Its impact is expected to be even more devastating in developing countries. In an attempt to minimize the impact of a pandemic, many countries are developing national and transnational plans against a possible influenza pandemic situation.

### **Sanofi Pasteur and Pandemic Preparedness**

Sanofi pasteur is committed to global pandemic preparedness. As the world leader in research, development and manufacturing of influenza vaccine, sanofi pasteur is actively involved in projects in the U.S. and Europe, with the goal of developing a vaccine to protect against a pandemic influenza virus.

Sanofi pasteur is also investing in major expansions of its influenza vaccine production facilities in the U.S. and France.

For more information please visit [www.sanofipasteur.com/pandemicpreparedness](http://www.sanofipasteur.com/pandemicpreparedness)

### **About sanofi-aventis**

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi pasteur, the vaccines division of the sanofi-aventis Group, provided more than a billion doses of vaccine in 2006, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The Company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: [www.sanofipasteur.com](http://www.sanofipasteur.com) or [www.sanofipasteur.us](http://www.sanofipasteur.us)

### **Forward Looking Statements**

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

###

### **C o n t a c t :**

#### **sanofi pasteur**

Pascal Barollier

International Media Relations

Tel: + 33-(0)4-37-37-51-41

[pascal.barollier@sanofipasteur.com](mailto:pascal.barollier@sanofipasteur.com)

#### **sanofi pasteur**

Len Lavenda

U.S. Media Relations

Tel: +1-570-839-4446

[len.lavenda@sanofipasteur.com](mailto:len.lavenda@sanofipasteur.com)